A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2016
At a glance
- Drugs GBS NN (Primary) ; Aluminium hydroxide
- Indications Streptococcal infections
- Focus Adverse reactions
- Sponsors Minervax
- 15 Sep 2016 Status changed from recruiting to completed.
- 10 Feb 2016 Planned End Date changed from 1 Jan 2017 to 1 Mar 2018, as reported by ClinicalTrials.gov.
- 10 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.